L'intérêt à découvert pour Shuttle Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Shuttle Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock, Rapport sur les intérêts à découvert

Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals Holdings Inc

SIHUAN PHARM HOLDINGS GP by Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd

SIHUAN PHARM HLDGS ADR by Sihuan Pharmaceutical Holdings Group Ltd.

Morgan Stanley analyst Stephen Byrd maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Overweight and lowers the price target from $109 to $104.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on American Electric Power, Lowers Price Target to $104

For decades, famed value investor&nbsp;Warren Buffett&nbsp;has insisted&nbsp;that he does not try to <a href="https://www.benzinga.com/personal-finance/24/04/38275323/warren-buffett-warns-dont-watch-the-market-closely-urges-not-to-obsessively-check-stock-prices-i">&#8220;time the market.&#8221;</a> But, his recent sales could serve as a warning sign for investors amid a period of protracted valuations.
What Happened: Buffett&#8217;s Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) has gradually wound down its largest positions over the last year.
Berkshire <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">slashed its largest position</a> in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) by over two-thirds since 2023. Buffett also sold much of his position in Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) since the summer. He also trimmed back nearly all of his position in Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), an atypically short holding period for the investor who preaches investing for the long term.
The Omaha, Nebraska-based company&#8217;s cash horde now stands at an astounding $325 billion.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42137295/as-mstrs-michael-saylor-says-warren-buffett-is-destroying-berkshire-capital-analyst-suggests-ove">As MSTR&#8217;s Michael Saylor Says Warren Buffett Is &#8216;Destroying&#8217; Berkshire Capital, Analyst Suggests &#8216;Overpriced…Hot Stock Market&#8217; Could Be The Reason Oracle Of Omaha Is Sitting On $325B Cash</a>
Why it Matters: Several market experts have struggled to comprehend Buffett&#8217;s thought process — is he bearish on the market at large? Reallocating his portfolio away from Apple and Bank of America to diversify? Or, as Buffett hinted at in May, anticipating a future change to U.S. tax laws?
An <a href="https://www.bloomberg.com/opinion/articles/2024-11-21/buffett-s-325-billion-cash-hoard-is-an-early-warning-signal?srnd=homepage-americas">article</a> from Bloomberg columnist Nir Kaissar could fuel the first theory. A <a href="https://x.com/cullenroche/status/1859644225991987508">post</a> on X relayed a graph from the article showing Buffett&#8217;s cash pile conspicuously rising ahead of financial crises.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Interesting piece here from <a href="https://twitter.com/markets?ref_src=twsrc%5Etfw">@markets</a> and how Buffett's cash hoard often spikes before equity market slowdowns. &#x1f914;&#x1f914;&#x1f914; <a href="https://t.co/9aFmsMpP2N">pic.twitter.com/9aFmsMpP2N</a>
&mdash; Cullen Roche (@cullenroche) <a href="https://twitter.com/cullenroche/status/1859644225991987508?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">The company&#8217;s cash allocation ticked upwards ahead of two large market crashes in 2000 and 2008.</figcaption></figure>
As companies in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) sustain a period of high valuations, Buffett could simply be heeding his advice, &#8220;to be fearful when&nbsp;others are greedy&nbsp;and to be greedy only when others are fearful,&#8221; allocating his portfolio away from what he deems riskier investments
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42140842/sp-500-faces-volatile-2025-as-inflation-boom-could-return-bank-of-america-strategist">S&amp;P 500 Faces Volatile 2025 As &#8216;Inflation Boom&#8217; Could Return: Bank Of America Strategist</a></li>
</ul>
Photo: Shutterstock

Equities

AAPL

ULTA

Warren Buffett Claims To Not 'Time The Market,' But His Cash Horde Tells A Different Story

Jefferies analyst Brent Thill maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Buy and raises the price target from $790 to $800.

INTU

Jefferies Maintains Buy on Intuit, Raises Price Target to $800

Morgan Stanley analyst Stephen Byrd maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Equal-Weight and lowers the price target from $88 to $86.

Morgan Stanley Maintains Equal-Weight on Ameren, Lowers Price Target to $86

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) for 11 euro ($11.44) per share in cash, implying a fully <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42137175/halozyme-withdraws-proposal-to-acquire-evotec-following-evotecs-unwillingness-to-engage-in-discuss" rel="noreferrer noopener">diluted equity value of 2.0 billion euro.</a>
This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.
In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.
The company expects revenue between $970 million and $1.02 billion ($1.003 billion) and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.
Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/11/42141413/us-business-activity-soars-to-31-month-highs-in-november-small-caps-rally-dow-tops-44000" rel="noreferrer noopener">US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000</a>
Helen Torley, CEO of Halozyme, explained that although the merger would have created a leading global pharma services company, Evotec was not open to further discussions.
Halozyme&#8217;s efforts to engage with Evotec&#8217;s leadership, including multiple requests for meetings, were unsuccessful, leading to the decision to withdraw the offer.
&#8220;A company spokesperson has publicly commented that its goal is to remain an independent company,&#8221; said Helen Torley,&nbsp;president and chief executive officer of Halozyme regarding Evotec, adding that &#8220;our multiple requests to meet were not accepted&#8221;.
&#8220;Evotec has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec for EUR11.00 per share in cash,&#8221; Evotec <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42141986/comment-on-withdrawn-non-binding-offer" rel="noreferrer noopener">said in a response.</a>
Price Action: HALO shares are trading higher by 6.21% to $48.54 at last check Friday, while EVO shares are down 18.8% to $4.345.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios" target="_blank" rel="noreferrer noopener">2025 US Economy Outlook&#8217; Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>

Markets

Movers

General

HALO

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Craig-Hallum analyst Richard Shannon maintains POET Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) with a Buy and raises the price target from $3.5 to $5.5.

POET

Craig-Hallum Maintains Buy on POET Technologies, Raises Price Target to $5.5

Janney Montgomery Scott analyst Christopher Marinac upgrades National Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKSH#NASDAQ">NKSH</a>) from Neutral to Buy and announces $38 price target.

Upgrades

NKSH

Janney Montgomery Scott Upgrades National Bankshares to Buy, Announces $38 Price Target

Craig-Hallum analyst Matthew Hewitt maintains Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) with a Buy and raises the price target from $8 to $10.

LFCR

Craig-Hallum Maintains Buy on Lifecore Biomedical, Raises Price Target to $10

Craig-Hallum analyst Jeff Van Rhee maintains Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Hold and raises the price target from $3.5 to $6.

CRNC

Craig-Hallum Maintains Hold on Cerence, Raises Price Target to $6

DA Davidson analyst Peter Heckmann initiates coverage on CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) with a Buy rating and announces Price Target of $36.

Initiation

PMTS

DA Davidson Initiates Coverage On CPI Card with Buy Rating, Announces Price Target of $36

Barrington Research analyst Gary Prestopino maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and raises the price target from $10 to $15.

AIOT

Barrington Research Maintains Outperform on PowerFleet, Raises Price Target to $15

RBC Capital analyst Scott Hanold maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Outperform and raises the price target from $102 to $116.

RBC Capital Maintains Outperform on Expand Energy, Raises Price Target to $116

IPOs

Trading Ideas

Ming Shing Group Shares Open For Trade At $5.65/Share; IPO Priced At $5.50/Share On 1.5M Shares

Canaccord Genuity analyst Susan Anderson maintains Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Buy and raises the price target from $5 to $6.

WALD

Canaccord Genuity Maintains Buy on Waldencast, Raises Price Target to $6

Macro Economic Events

Economics

Biden Administration Approves New York Plan To Launch $9 Congestion Fee Starting Jan. 5

RBC Capital analyst Rishi Jaluria reiterates Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Outperform and maintains $760 price target.

Reiteration

RBC Capital Reiterates Outperform on Intuit, Maintains $760 Price Target

During the last three months, 4 analysts shared their evaluations of Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $87.25, with a high estimate of $100.00 and a low estimate of $76.00. Experiencing a 3.59% decline, the current average is now lower than the previous average price target of $90.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294863_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Keros Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$76.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Keros Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Keros Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Keros Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Keros Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KROS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Keros Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Keros Therapeutics</h2>
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
<h3>Financial Insights: Keros Therapeutics</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Keros Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4750.0% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Keros Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -13648.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Keros Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.24%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Keros Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KROS

Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

ICF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.75, a high estimate of $185.00, and a low estimate of $140.00. Observing a 0.05% increase, the current average has risen from the previous average price target of $169.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294854_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive ICF International. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$140.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Marc Riddick</td>
<td>Sidoti &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$180.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$174.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ICF International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ICF International compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ICF International's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ICF International's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICFI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICF International analyst ratings.</a>
<h2>All You Need to Know About ICF International</h2>
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian &amp; Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in single segment, which is providing professional services.
<h3>Key Indicators: ICF International's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, ICF International showcased positive performance, achieving a revenue growth rate of 3.09% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: ICF International's net margin excels beyond industry benchmarks, reaching 6.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ICF International's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.4%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): ICF International's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.62%, the company may face hurdles in achieving optimal financial performance.
Debt Management: ICF International's debt-to-equity ratio is below the industry average at 0.63, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICFI

Expert Outlook: ICF International Through The Eyes Of 4 Analysts

Across the recent three months, 5 analysts have shared their insights on Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $117.6, along with a high estimate of $125.00 and a low estimate of $110.00. Witnessing a positive shift, the current average has risen by 4.44% from the previous average price target of $112.60.
<img src="https://www.benzinga.com/files/images/story/2024/1732294842_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Parsons by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$122.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Brian Gesuale</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$99.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Parsons. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Parsons compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Parsons's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Parsons's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PSN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Parsons analyst ratings.</a>
<h2>Delving into Parsons's Background</h2>
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
<h3>Parsons's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Parsons showcased positive performance, achieving a revenue growth rate of 27.6% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.97%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Parsons's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.18%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.35%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.6, Parsons adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 5 Analyst Ratings For Parsons

Canaccord Genuity analyst David Hynes maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Buy and raises the price target from $67 to $83.

PCOR

Canaccord Genuity Maintains Buy on Procore Technologies, Raises Price Target to $83

Shuttle Pharma regains compliance with Nasdaq minimum bid price requirement

Shuttle Pharmaceuticals files for offering common stock, warrants

An announcement from Shuttle Pharmaceuticals Holdings, Inc. ( ($SHPH) ) is now available. Shuttle Pharmaceuticals Holdings is set to present at the...

Shuttle Pharmaceuticals to Present at ThinkEquity Conference

Shuttle Pharmaceuticals Holdings, Inc. ( ($SHPH) ) just unveiled an update. Shuttle Pharmaceuticals Holdings has finalized agreements with six canc...

Shuttle Pharmaceuticals Advances Glioblastoma Clinical Trials

Shuttle Pharmaceuticals (SHPH) Holdings announced it has finalized agreements with all six of the planned site enrollment locations to administer t...

Shuttle's clinical trial site enrollments complete for Phase 2 of IPdR for GBM

Shuttle Pharmaceuticals (SHPH) announced that the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patient...

Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine

Shuttle Pharmaceuticals Holdings, Inc. ( ($SHPH) ) has issued an announcement. Shuttle Pharmaceuticals has announced the successful dosing of the f...

Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial

Shuttle Pharmaceuticals (SHPH) announced the pricing of its "reasonable best efforts" public offering with a health-care focused institutional inve...

Comments

Shuttle Pharmaceuticals

Intérêt court

Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL